FARALLON CAPITAL MANAGEMENT LLC
13F Reported Value
ⓘ$17.5B
incl. option notional
Equity Holdings
ⓘ$15.3B
Option Notional
ⓘ$2.2B
$2.2B puts / $13.5M calls
Holdings
172
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
FARALLON CAPITAL MANAGEMENT LLC disclosed 172 positions worth $17.5B in its Form 13F-HR for Q1 2026 — $15.3B in common stock plus $2.2B of put/call option positions (reported at underlying notional value, not premium at risk), led by $SPY (SPDR S&P 500 ETF TRUST) puts, followed by $RVMD and $AMZN. During the quarter the fund opened 48 new positions and exited 28 — including a new stake in $DNTH. The portfolio is most concentrated in Healthcare (53.3% of disclosed assets). All figures are sourced directly from FARALLON CAPITAL MANAGEMENT LLC’s Form 13F-HR filing with the SEC under CIK 909661.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$1.5B2,300,000 sh - —
Quality
$1.3B13,604,796 sh - 74.6#152
Quality
$878.6M4,218,394 sh - 83.7
Quality
$868.0M2,344,779 sh - —
Quality
$811.0M2,512,638 sh - 31.7
Quality
$695.5M9,365,463 sh INVESCO EXCHANGE TRADED FD T PUT
—Quality
$690.9M3,600,000 sh- 24.8
Quality
$669.2M6,348,906 sh - 46.4
Quality
$641.4M3,207,366 sh - 79.4
Quality
$562.3M13,111,010 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 SPDR S&P 500 ETF TRUST$SPYPUT | — | $1.5B | 2,300,000 |
 Revolution Medicines, Inc.$RVMD | — | $1.3B | 13,604,796 |
 AMAZON COM INC$AMZN | 74.6#152 | $878.6M | 4,218,394 |
 MICROSOFT CORP$MSFT | 83.7 | $868.0M | 2,344,779 |
 Aon plc$AON | — | $811.0M | 2,512,638 |
 BridgeBio Pharma, Inc.$BBIO | 31.7 | $695.5M | 9,365,463 |
| INVESCO EXCHANGE TRADED FD T PUT | — | $690.9M | 3,600,000 |
 Protagonist Therapeutics, Inc$PTGX | 24.8 | $669.2M | 6,348,906 |
 Natera, Inc.$NTRA | 46.4 | $641.4M | 3,207,366 |
 EXELIXIS, INC.$EXEL | 79.4 | $562.3M | 13,111,010 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of FARALLON CAPITAL MANAGEMENT LLC's 172 positions.
Showing top 10 of 172 holdings.
Sector Allocation
Healthcare
$8.2B
Technology
$2.8B
Financials
$2.2B
Consumer Discretionary
$1.1B
Industrials
$446.2M
Consumer Staples
$280.8M
Communication Services
$231.5M
Other
$44.6M
Full Holdings — FARALLON CAPITAL MANAGEMENT LLC (Q1 2026)
All 172 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $SPYPUT | SPDR S&P 500 ETF TRUST | $1.5B | — | -23% | — |
| 2 | $RVMD | Revolution Medicines, Inc. | $1.3B | 8.6% | -7% | — |
| 3 | $AMZN | AMAZON COM INC | $878.6M | 5.7% | -6% | 74.6 |
| 4 | $MSFT | MICROSOFT CORP | $868.0M | 5.7% | +6% | 83.7 |
| 5 | $AON | Aon plc | $811.0M | 5.3% | -6% | — |
| 6 | $BBIO | BridgeBio Pharma, Inc. | $695.5M | 4.5% | +4% | 31.7 |
| 7 | — | INVESCO EXCHANGE TRADED FD T | $690.9M | — | +0% | — |
| 8 | $PTGX | Protagonist Therapeutics, Inc | $669.2M | 4.4% | +3% | 24.8 |
| 9 | $NTRA | Natera, Inc. | $641.4M | 4.2% | -18% | 46.4 |
| 10 | $EXEL | EXELIXIS, INC. | $562.3M | 3.7% | -17% | 79.4 |
| 11 |  $AVGO | Broadcom Inc. | $550.8M | 3.6% | +99% | 86.4 |
| 12 |  $UNH | UNITEDHEALTH GROUP INC | $492.9M | 3.2% | +14% | 66.8 |
| 13 |  $SNPS | SYNOPSYS INC | $481.0M | 3.1% | +21% | 63.1 |
| 14 |  $BSX | BOSTON SCIENTIFIC CORP | $468.8M | 3.1% | +0% | 79.9 |
| 15 |  $TMO | THERMO FISHER SCIENTIFIC INC. | $433.3M | 2.8% | +39% | 63.7 |
| 16 |  $KKR | KKR & Co. Inc. | $432.1M | 2.8% | +132% | 49.8 |
| 17 |  $LNTH | Lantheus Holdings, Inc. | $423.5M | 2.8% | +3% | 66.9 |
| 18 |  $WAB | WESTINGHOUSE AIR BRAKE TECHNOLOGIES CORP | $402.2M | 2.6% | -35% | 70.8 |
| 19 |  $SCHW | SCHWAB CHARLES CORP | $371.8M | 2.4% | +18% | 77.2 |
| 20 |  $LQDA | Liquidia Corp | $326.7M | 2.1% | +0% | 37.4 |
| 21 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $302.8M | 2.0% | +20% | 26.5 |
| 22 |  $GOOGL | Alphabet Inc. | $285.8M | 1.9% | +27% | 80.2 |
| 23 |  $ROIV | Roivant Sciences Ltd. | $268.0M | 1.8% | NEW | — |
| 24 |  $V | VISA INC. | $254.1M | 1.7% | +21% | 83.5 |
| 25 |  $ARMK | Aramark | $248.7M | 1.6% | -34% | 53 |
| 26 |  $BEAM | Beam Therapeutics Inc. | $241.5M | 1.6% | +1% | 12.1 |
| 27 |  $DIS | Walt Disney Co | $231.5M | 1.5% | -42% | 68.9 |
| 28 |  $MA | Mastercard Inc | $217.4M | 1.4% | +152% | 81.7 |
| 29 |  $MCK | MCKESSON CORP | $202.8M | 1.3% | -22% | 63.7 |
| 30 |  $AGIO | AGIOS PHARMACEUTICALS, INC. | $192.3M | 1.3% | +10% | 26.3 |
| 31 |  $CNTA | Centessa Pharmaceuticals plc | $191.0M | 1.2% | -11% | — |
| 32 |  $TNGX | Tango Therapeutics, Inc. | $190.3M | 1.2% | -30% | 26.9 |
| 33 |  $GRAL | GRAIL, Inc. | $168.2M | 1.1% | +39% | 31.9 |
| 34 |  $TYRA | Tyra Biosciences, Inc. | $137.1M | 0.9% | +73% | — |
| 35 |  $THC | TENET HEALTHCARE CORP | $85.3M | 0.6% | +21% | 66.6 |
| 36 |  $CAH | CARDINAL HEALTH INC | $77.8M | 0.5% | -36% | 58.6 |
| 37 |  $PCVX | Vaxcyte, Inc. | $73.3M | 0.5% | NEW | — |
| 38 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $70.2M | 0.5% | NEW | 26.8 |
| 39 |  $BTSG | BrightSpring Health Services, Inc. | $68.9M | 0.5% | +7250% | 64.3 |
| 40 |  $TWST | Twist Bioscience Corp | $67.8M | 0.4% | NEW | 33.3 |
| 41 |  $BIDU | Baidu, Inc. | $49.4M | 0.3% | +41% | — |
| 42 |  $CGON | CG Oncology, Inc. | $45.6M | 0.3% | +8325% | 28 |
| 43 |  $AZN | ASTRAZENECA PLC | $44.7M | 0.3% | NEW | — |
| 44 | — | VNET GROUP INC | $44.5M | 0.3% | +616% | — |
| 45 |  $MRK | Merck & Co., Inc. | $43.4M | 0.3% | NEW | 70.9 |
| 46 |  $ACHC | Acadia Healthcare Company, Inc. | $40.6M | 0.3% | NEW | 49.3 |
| 47 |  $WELL | WELLTOWER INC. | $39.5M | 0.3% | -42% | 75.7 |
| 48 |  $IMVT | Immunovant, Inc. | $38.4M | 0.3% | NEW | — |
| 49 |  $ENTA | ENANTA PHARMACEUTICALS INC | $36.3M | 0.2% | +4% | 15.5 |
| 50 |  $JNJ | JOHNSON & JOHNSON | $36.2M | 0.2% | NEW | 72.8 |
| 51 |  $BBNX | Beta Bionics, Inc. | $36.2M | 0.2% | -16% | 22.8 |
| 52 |  $ASMB | ASSEMBLY BIOSCIENCES, INC. | $34.1M | 0.2% | +0% | 26.6 |
| 53 |  $JOYY | JOYY Inc. | $33.8M | 0.2% | +0% | — |
| 54 |  $MSTR | Strategy Inc | $32.9M | 0.2% | NEW | 25.4 |
| 55 |  $NTES | NetEase, Inc. | $32.6M | 0.2% | NEW | — |
| 56 |  $NVO | NOVO NORDISK A S | $28.7M | 0.2% | NEW | — |
| 57 |  $BITW | Bitwise 10 Crypto Index ETF | $26.9M | 0.2% | -82% | — |
| 58 |  $PCSC | Perceptive Capital Solutions Corp | $24.7M | 0.2% | +0% | — |
| 59 |  $RPRX | Royalty Pharma plc | $23.6M | 0.1% | NEW | — |
| 60 |  $NERV | Minerva Neurosciences, Inc. | $14.2M | 0.1% | +0% | — |
| 61 |  $CECO | CECO ENVIRONMENTAL CORP | $13.9M | 0.1% | NEW | 62.8 |
| 62 |  $AVTX | Avalo Therapeutics, Inc. | $13.7M | 0.1% | NEW | 4.6 |
| 63 | $CGONCALL | CG Oncology, Inc. | $13.5M | — | NEW | 28 |
| 64 |  $GDS | GDS Holdings Ltd | $11.8M | 0.1% | NEW | — |
| 65 |  $MAZE | Maze Therapeutics, Inc. | $11.1M | 0.1% | NEW | 19.7 |
| 66 |  $TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $10.7M | 0.1% | +785% | — |
| 67 |  $FORM | FORMFACTOR INC | $5.5M | 0.0% | NEW | 54 |
| 68 |  $MTZ | MASTEC INC | $5.5M | 0.0% | NEW | 59.7 |
| 69 |  $ENTG | ENTEGRIS INC | $5.3M | 0.0% | NEW | 57.7 |
| 70 |  $C | CITIGROUP INC | $5.3M | 0.0% | NEW | 54.8 |
| 71 |  $VNET | VNET Group, Inc. | $5.2M | 0.0% | -90% | — |
| 72 |  $H | Hyatt Hotels Corp | $5.2M | 0.0% | NEW | 46.6 |
| 73 |  $WAL | WESTERN ALLIANCE BANCORPORATION | $5.2M | 0.0% | NEW | 56.1 |
| 74 |  $TKR | TIMKEN CO | $5.1M | 0.0% | NEW | 50.7 |
| 75 |  $FLEX | FLEX LTD. | $5.1M | 0.0% | NEW | — |
| 76 |  $SPGI | S&P Global Inc. | $5.1M | 0.0% | NEW | 79.4 |
| 77 |  $LFUS | LITTELFUSE INC /DE | $5.1M | 0.0% | NEW | 58.7 |
| 78 |  $PIPR | PIPER SANDLER COMPANIES | $5.1M | 0.0% | NEW | 64.4 |
| 79 |  $AIR | AAR CORP | $5.0M | 0.0% | NEW | 65.3 |
| 80 |  $RIO | RIO TINTO PLC | $5.0M | 0.0% | NEW | — |
| 81 |  $GTX | Garrett Motion Inc. | $5.0M | 0.0% | NEW | 59.6 |
| 82 |  $ROL | ROLLINS INC | $5.0M | 0.0% | NEW | 73.2 |
| 83 |  $AFRM | Affirm Holdings, Inc. | $4.9M | 0.0% | NEW | 71.7 |
| 84 |  $INTR | Inter & Co, Inc. | $4.9M | 0.0% | NEW | — |
| 85 |  $CMI | CUMMINS INC | $4.8M | 0.0% | NEW | 58.9 |
| 86 |  $FISV | FISERV INC | $4.8M | 0.0% | NEW | 67.4 |
| 87 |  $VRT | Vertiv Holdings Co | $4.8M | 0.0% | NEW | 82.7 |
| 88 |  $AMKR | AMKOR TECHNOLOGY, INC. | $4.7M | 0.0% | -78% | 53 |
| 89 |  $RNA | Avidity Biosciences, Inc. | $4.7M | 0.0% | NEW | 22.3 |
| 90 |  $GFS | GLOBALFOUNDRIES Inc. | $4.7M | 0.0% | NEW | — |
| 91 |  $MOH | MOLINA HEALTHCARE, INC. | $4.7M | 0.0% | NEW | 60.5 |
| 92 |  $IRD | Opus Genetics, Inc. | $4.5M | 0.0% | NEW | — |
| 93 |  $TENB | Tenable Holdings, Inc. | $4.5M | 0.0% | NEW | 51.9 |
| 94 |  $PRME | Prime Medicine, Inc. | $4.3M | 0.0% | +0% | 11.2 |
| 95 |  $NOW | ServiceNow, Inc. | $4.3M | 0.0% | NEW | 76 |
| 96 |  $SMC | Summit Midstream Corp | $1.8M | 0.0% | +0% | 30 |
| 97 |  $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $1.7M | 0.0% | +0% | 25.4 |
| 98 |  $CAPR | CAPRICOR THERAPEUTICS, INC. | $1.2M | 0.0% | +0% | — |
| 99 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $990,660 | 0.0% | +0% | 74.4 |
| 100 |  $ANNA | AleAnna, Inc. | $801,900 | 0.0% | +0% | 47 |
| 101 |  $GH | Guardant Health, Inc. | $738,960 | 0.0% | -93% | 36.1 |
| 102 |  $ALKS | Alkermes plc. | $735,488 | 0.0% | +0% | — |
| 103 |  $ALVO | Alvotech | $684,885 | 0.0% | +0% | — |
| 104 |  $AXSM | Axsome Therapeutics, Inc. | $676,080 | 0.0% | +0% | 36.6 |
| 105 |  $COGT | Cogent Biosciences, Inc. | $654,330 | 0.0% | +0% | — |
| 106 | $ANNA | AleAnna, Inc. | $649,936 | 0.0% | +0% | 47 |
| 107 |  $ARQT | Arcutis Biotherapeutics, Inc. | $612,560 | 0.0% | +0% | 41.2 |
| 108 |  $CELC | Celcuity Inc. | $456,560 | 0.0% | +0% | — |
| 109 |  $LIVN | LivaNova PLC | $381,360 | 0.0% | +0% | — |
| 110 |  $TERN | Terns Pharmaceuticals, Inc. | $369,040 | 0.0% | -99% | — |
| 111 |  $IONS | IONIS PHARMACEUTICALS INC | $360,432 | 0.0% | +0% | 37.1 |
| 112 |  $TVTX | Travere Therapeutics, Inc. | $356,520 | 0.0% | +0% | 39.2 |
| 113 |  $GMED | GLOBUS MEDICAL INC | $344,640 | 0.0% | +0% | 77.6 |
| 114 |  $SRRK | Scholar Rock Holding Corp | $344,120 | 0.0% | +0% | — |
| 115 |  $ONC | BeOne Medicines Ltd. | $326,667 | 0.0% | +0% | — |
| 116 |  $WGS | GeneDx Holdings Corp. | $321,100 | 0.0% | -93% | 38.6 |
| 117 |  $COR | Cencora, Inc. | $314,140 | 0.0% | +0% | 59.6 |
| 118 |  $NUVL | Nuvalent, Inc. | $307,350 | 0.0% | +0% | — |
| 119 |  $PGNY | Progyny, Inc. | $305,640 | 0.0% | +0% | 59 |
| 120 |  $STOK | Stoke Therapeutics, Inc. | $293,040 | 0.0% | +0% | 53.4 |
| 121 |  $ERAS | Erasca, Inc. | $291,240 | 0.0% | NEW | — |
| 122 |  $EHC | Encompass Health Corp | $290,190 | 0.0% | -99% | 68.9 |
| 123 |  $NKTR | NEKTAR THERAPEUTICS | $287,800 | 0.0% | NEW | 10.2 |
| 124 |  $GKOS | GLAUKOS Corp | $279,916 | 0.0% | +0% | 39.2 |
| 125 |  $MIRM | Mirum Pharmaceuticals, Inc. | $277,140 | 0.0% | +0% | 32.7 |
| 126 |  $SBRA | Sabra Health Care REIT, Inc. | $269,220 | 0.0% | +0% | 73.5 |
| 127 |  $KRYS | Krystal Biotech, Inc. | $258,320 | 0.0% | -50% | 75.9 |
| 128 |  $OMER | OMEROS CORP | $242,880 | 0.0% | +0% | — |
| 129 |  $ALMS | ALUMIS INC. | $242,330 | 0.0% | NEW | 9.2 |
| 130 |  $APLS | Apellis Pharmaceuticals, Inc. | $241,380 | 0.0% | NEW | 63.9 |
| 131 |  $HQY | HEALTHEQUITY, INC. | $233,996 | 0.0% | -44% | 72.3 |
| 132 |  $SNDX | Syndax Pharmaceuticals Inc | $233,600 | 0.0% | +0% | 30 |
| 133 |  $FOLD | AMICUS THERAPEUTICS, INC. | $231,360 | 0.0% | +0% | 44.2 |
| 134 |  $QURE | uniQure N.V. | $228,900 | 0.0% | +0% | — |
| 135 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $228,480 | 0.0% | +0% | 37.2 |
| 136 |  $VCYT | VERACYTE, INC. | $225,470 | 0.0% | +0% | 59.5 |
| 137 |  $GRFS | Grifols SA | $224,560 | 0.0% | +0% | — |
| 138 |  $ABVX | Abivax S.A. | $222,700 | 0.0% | -99% | — |
| 139 |  $GEHC | GE HealthCare Technologies Inc. | $213,540 | 0.0% | +0% | 58.2 |
| 140 | $RVMD | Revolution Medicines, Inc. | $208,948 | 0.0% | +0% | — |
| 141 |  $HIMS | Hims & Hers Health, Inc. | $207,600 | 0.0% | -100% | 50.9 |
| 142 |  $BLTE | BELITE BIO, INC | $207,272 | 0.0% | NEW | — |
| 143 |  $MMSI | MERIT MEDICAL SYSTEMS INC | $206,790 | 0.0% | +0% | 60.1 |
| 144 |  $SUPN | SUPERNUS PHARMACEUTICALS, INC. | $206,760 | 0.0% | NEW | 45.3 |
| 145 |  $HR | Healthcare Realty Trust Inc | $203,880 | 0.0% | +0% | 44.9 |
| 146 |  $URGN | UroGen Pharma Ltd. | $197,780 | 0.0% | +0% | — |
| 147 |  $VIR | Vir Biotechnology, Inc. | $197,120 | 0.0% | NEW | 5.6 |
| 148 |  $PGEN | PRECIGEN, INC. | $193,500 | 0.0% | +0% | 38.6 |
| 149 |  $SDGR | Schrodinger, Inc. | $193,120 | 0.0% | -76% | 31 |
| 150 |  $DYN | Dyne Therapeutics, Inc. | $181,300 | 0.0% | +0% | — |
| 151 |  $NVAX | NOVAVAX INC | $179,080 | 0.0% | -89% | 65.5 |
| 152 |  $PACB | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | $178,200 | 0.0% | +0% | 10.8 |
| 153 |  $SLS | SELLAS Life Sciences Group, Inc. | $169,200 | 0.0% | NEW | — |
| 154 |  $ADPT | Adaptive Biotechnologies Corp | $152,680 | 0.0% | +0% | 35.2 |
| 155 |  $OCUL | OCULAR THERAPEUTIX, INC | $152,460 | 0.0% | +0% | 12.8 |
| 156 |  $NEO | NEOGENOMICS INC | $140,980 | 0.0% | +0% | 34.6 |
| 157 |  $ARDX | ARDELYX, INC. | $137,770 | 0.0% | +0% | 35.3 |
| 158 |  $OSCR | Oscar Health, Inc. | $126,170 | 0.0% | -96% | 70.4 |
| 159 |  $NUVB | Nuvation Bio Inc. | $124,410 | 0.0% | +0% | 29.5 |
| 160 |  $IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $91,260 | 0.0% | +0% | 30.6 |
| 161 | — | SOLID POWER INC | $88,359 | 0.0% | +0% | — |
| 162 |  $ALT | Altimmune, Inc. | $85,008 | 0.0% | +0% | 7.3 |
| 163 |  $CCCC | C4 Therapeutics, Inc. | $73,640 | 0.0% | +0% | 6.5 |
| 164 |  $TVRD | Tvardi Therapeutics, Inc. | $68,173 | 0.0% | -50% | — |
| 165 |  $GERN | GERON CORP | $64,070 | 0.0% | +0% | — |
| 166 |  $BGL | Blue Gold Ltd | $60,000 | 0.0% | +0% | — |
| 167 |  $RANI | Rani Therapeutics Holdings, Inc. | $57,314 | 0.0% | +0% | — |
| 168 |  $IRWD | IRONWOOD PHARMACEUTICALS INC | $45,630 | 0.0% | +0% | 55.9 |
| 169 |  $EVH | Evolent Health, Inc. | $31,920 | 0.0% | +0% | 31.5 |
| 170 |  $CGC | Canopy Growth Corp | $28,476 | 0.0% | +0% | 20.1 |
| 171 |  $NVNI | Nvni Group Ltd | $17,813 | 0.0% | +0% | — |
| 172 |  $BYND | BEYOND MEAT, INC. | $13,330 | 0.0% | +0% | 13.1 |
New Positions (48)
$DNTH Dianthus Therapeutics, Inc. /DE/$70.2M$AZN ASTRAZENECA PLC$44.7M$MRK Merck & Co., Inc.$43.4M$ACHC Acadia Healthcare Company, Inc.$40.6M$JNJ JOHNSON & JOHNSON$36.2M$MSTR Strategy Inc$32.9M$NTES NetEase, Inc.$32.6M$NVO NOVO NORDISK A S$28.7M$RPRX Royalty Pharma plc$23.6M$CECO CECO ENVIRONMENTAL CORP$13.9M$AVTX Avalo Therapeutics, Inc.$13.7M$CGONCALL CG Oncology, Inc.$13.5M$GDS GDS Holdings Ltd$11.8M$MAZE Maze Therapeutics, Inc.$11.1M$FORM FORMFACTOR INC$5.5MExited Positions (28)
$CYBR CyberArk Software Ltd.
$LLYPUT ELI LILLY & Co
$CRM Salesforce, Inc.
$NDAQ NASDAQ, INC.
$NYT NEW YORK TIMES CO
$CBRE CBRE GROUP, INC.
$IBIT iShares Bitcoin Trust ETF
$TRU TransUnion
$INSMCALL INSMED Inc
$ALNYPUT ALNYLAM PHARMACEUTICALS, INC.
$ETHA iShares Ethereum Trust ETF
$GPCR Structure Therapeutics Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for FARALLON CAPITAL MANAGEMENT LLC including:
Track FARALLON CAPITAL MANAGEMENT LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for FARALLON CAPITAL MANAGEMENT LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: FARALLON CAPITAL MANAGEMENT LLC
13F Pro is an AI hedge fund tracker and stock research platform. For FARALLON CAPITAL MANAGEMENT LLC (SEC CIK: 909661), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in FARALLON CAPITAL MANAGEMENT LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.